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Abstract
Background: Ocular damage from radiation treatment is a well established phenomenon. Many
factors are now known to influence the incidence of radiation retinopathy, including total dosage
and daily fraction size. Patients who are diabetic, hypertensive or received previous chemotherapy
are more susceptible to radiation retinopathy.
Case Presentation: A 55 year old male was referred from the oncology department with
epiphora. His medical history included Type 2 Insulin treated Diabetes Mellitus and hypertension.
One year prior to presentation he had undergone a total rhinectomy with a 4 week course of post-
operative radiotherapy for an aggressive sqaumous cell carcinoma of the nose. On examination the
visual acuity was noted to be 6/36 left eye and 6/9 right eye. Posterior segment examination
revealed marked retinal ischaemia present in the posterior pole and macular region of both eyes.
The appearance was not thought to be typical of diabetic changes, radiation retinopathy being the
more likely diagnosis especially in view of his history. Over the next four months the vision in both
eyes rapidly deteriorated to 3/60 left eye and 1/60 right eye. Bilateral pan retinal photocoagulation
was thought to be appropriate treatment at this point.
Conclusion: This case highlights the importance for ophthalmologists and oncologists to be aware
of the close relationship between diabetes and radiation treatment and the profound rapid impact
this combination of factors may have on visual function. Radiation is being used with increasing
frequency for ocular and orbital disease, because of this more cases of radiation retinopathy may
become prevalent. Factors which may potentiate radiation retinopathy should be well known
including, increased radiation dosage, increased fraction size, concomitant systemic vascular disease
and use of chemotherapy. Counselling should be offered in all cases at risk of visual loss. As no
effective treatment currently exists to restore visual function, monitoring of visual acuity in all cases
and early referral to the ophthalmologist as appropriate is warranted.
Background
Ocular damage from radiation treatment is a well estab-
lished phenomenon. Many factors are now known to
influence the incidence of radiation retinopathy, includ-
ing total dosage and daily fraction size. Patients who are
diabetic, hypertensive or who have received previous
chemotherapy are more susceptible to radiation retinopa-
thy. In this article we describe a case of a man who devel-
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precautions, due to the confounding problem of diabetes.
We also discuss the current literature on radiation retinop-
athy.
Case Presentation
A 55 year old male was referred from the oncology depart-
ment with epiphora. His medical history included type 2,
Insulin treated, Diabetes Mellitus of 10-years duration
and controlled hypertension. He smoked between 20–40
cigarettes per day. One year prior to presentation he had
undergone a total rhinectomy with a 4 week course of
post-operative radiotherapy for an aggressive sqaumous
cell carcinoma of the nose (see figure 1). He received a
total of 5250 rad (52.5 gray) to the tumour (1312.5 rad/
13.12 gray per week, 262.5 rad/2.62 gray per session).
Since treatment there had been no evidence of tumour
recurrence. He underwent diabetic eye screening through
his optometrist and a diabetic retinal check in April 2005
was recorded as showing no diabetic eye disease. There
was no other ocular history of note.
On examination the visual acuity was noted to be 6/36 left
eye and 6/9 right eye. He had bilateral medial lower lid
ectropion accounting for the epiphora. Anterior segment
examination and intraocular pressures were normal. Pos-
terior segment examination revealed marked retinal
ischaemia present in the posterior pole and macular
region of both eyes. Fundus fluorescein angiography
(FFA) confirmed an ischaemic retina. There were no signs
of neovascularization (see figure 2). The distribution of
the retinal changes with severe ischaemic changes in the
posterior retina more than in the anterior retina, the rela-
tive lack of microaneurysms compared to the high num-
bers of cotton wool spots and blot haemorrhages and the
rapid nature in which the retinopathy developed made
the diagnosis of radiation retinopathy likely. Additionally
the temporal onset of the retinopathy in relation to the
radiotherapy (1 year post treatment) and the dose deliv-
ered further supported this diagnosis. Over the next four
months the vision in both eyes rapidly deteriorated to 3/
60 left eye and 1/60 right eye. Clinical examination
revealed bilateral vitreous haemorrhage. FFA confirmed
bilateral disc neovascularisation and evidence of a grossly
ischaemic retina with little residual viable retina (see fig-
ure 3). Bilateral pan retinal photocoagulation was consid-
ered to be appropriate treatment at this stage as it was
thought that the minimal remaining, highly ischaemic,
retina close to the arcades may be responsible for the disc
neovascularisation. The total area of treatment in RE was
2595 mm2 and in the LE 1825 mm2. At review in Septem-
ber 2006 the visual acuities were counting fingers in the
RE and 6/60 aided in the LE. The retinopathy is stable.
Conclusion
The clinical features of radiation retinopathy include
microaneurysms, cotton wool spots, capillary dilation,
telangectasia, and capillary closure. The posterior retina is
more sensitive to radiation than the peripheral retina [1-
3]. Vascular compromise may result in retinal oedema.
Ischaemia may lead to disc neovascularization which in
turn can cause vitreous haemorrhage and retinal detach-
ment. Histologically there is thickening of arteriolar and
capillary walls and loss of endothelial cells [1-3]. Histo-
logically these findings differ from diabetic retinopathy in
that there is early loss of endothelial cells in radiation
retinopathy compared to diabetic retinopathy where peri-
cytes are affected initially. There are also less number of
microaneurysms present compared to diabetic retinopa-
thy, this was noted in our patient favouring a diagnosis of
radiation retinopathy [1,3].
The total dose of radiation, along with the fraction size are
important in the development of retinopathy[1-4]. A
reported safe dose is 3000 rads/30 Gray, 1000 rads/10
Gray per week in five fractions (200 rads/2 Gray per ses-
sion) [3], although cases have been reported with lower
doses of radiotherapy [2,4]. One study reported 50% of
patients developed retinopathy following 60 Gray [5] of
radiation whilst another report showed a rise in incidence
to 85–95% in those exposed to 70–80 Gray [6]. The time
of onset of radiation retinopathy is between 6 months – 3
years, again it has been known to occur earlier or later [2].
CT Scan showing area of sqaumous cell carcinomaFigure 1
CT Scan showing area of sqaumous cell carcinoma.Page 2 of 5
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dose due to the aggressive nature of the carcinoma. It is
likely that this combined with pre-existing diabetes
resulted in the severe and rapid progression of retinopathy
one year after treatment.
Factors which are known to exacerbate radiation retinop-
athy include chemotherapy and vascular diseases such as
diabetes and hypertension[3,7-9]. Pregnancy has been
thought to accelerate radiation retinopathy [10] and is
also known to aggravate diabetic retinopathy [11].
Spontaneous improvement can occur but this is infre-
quent [12]. Mostly treatment with pan retinal photocoag-
ulation is implemented when neovascularization is
visible [1]. One study found 91% of patients treated with
PRP for proliferative radiation retinopathy had regression
of new vessels [13].
Ocular manifestations of radiotherapy are well known
and include dry eye, epiphora, ectropion, scleral necrosis,
cataract, glaucoma, optic neuropathy and retinopathy
[14] Cataracts and radiation retinopathy are the most
common visually limiting complications seen after oph-
thalmic plaque radiation therapy [15]. The cataracts are
amenable to surgical treatment mostly leading to
improvement in vision. However, retinopathy can lead to
permanent and severe visual loss. Currently no guidelines
or treatment exists for radiation retinopathy. Pan Retinal
Photocoagulation is performed in the proliferative stage
in an attempt to prevent further visual loss, although stud-
ies have shown that earlier intervention may be more ben-
eficial in preserving vision [16]. There are studies which
have reported a temporary improvement in vision after
using intravitreal triamcinolone [17,18] or focal laser
treatment for cases with radiation maculopathy [19].
Recently a classification has been devised by Finger and
Kurli [14] which describes stages of radiation retinopathy
in relation to the clinical signs seen, symptoms, location,
best method of visualization and the risk of vision loss.
This is important as there is a need for common language
for this retinopathy for future comparative studies. Our
patient was initially asymptomatic and found to have cot-
ton wool spots, retinal haemorrhages, exudates, chorio-
dopathy and retinal ischaemia involving posterior pole
and peripheral retina. These findings relate to stage 2 of
Finger's radiation retinopathy classification, stage 2 carries
a guarded prognosis for vision having a moderate risk of
visual loss. The patient rapidly progressed over 4 months
to stage 4, where visual loss did occur and retinal neovas-
cularisation along with vitreous haemorrhage was
present.
Radiation retinopathy prior to laser treatmentFigure 3
Radiation retinopathy prior to laser treatment. The 
photographs above show increasing severity of the radiation 
retinopathy with evidence of bilateral vitreous haemorrhage 
secondary to disc neovascularization. Severe ischaemic areas 
and areas of non-viable peripheral retina are visible, an area 
of viable ischemic retina along the arcades close to the disc is 
thought to be responsible for the disc noevascularisation.
Radiation Retinopathy at initial presentationFigure 2
Radiation Retinopathy at initial presentation. The col-
our fundus photographs above show clinical evidence of 
marked bilateral ischaemic changes. The fluorescein photo-
graphs show evidence of masking from the haemorrhages 
and also areas of capillary dropout reflecting ischaemic areas.Page 3 of 5
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tion is useful in inducing regression of radiation retinop-
athy and also that treatment before clinically apparent
radiation retinopathy is present may be more effective
than treatment after its onset, especially in high risk cases.
This is especially important in cases of radiation maculop-
athy as prevention is more likely to preserve vision than
treatment after its onset. This results of this study also sug-
gest that treatment of cases with no clinical evidence of
retinopathy were less likely to develop maculopathy post
laser treatment. This highlights the need for monitoring
visual acuity post radiation treatment, especially in high
risk cases [16].
This case highlights the importance for ophthalmologists
and oncologists to be aware of the close relationship
between diabetes and radiation treatment and the pro-
found rapid impact this combination of factors may have
on visual function. It is unlikely that the rapid progression
of retinopathy and dramatic loss of vision in this patient
was due to diabetes alone. He was not noted by his opti-
cian to have any prior diabetic retinopathy and at his
blood pressure was well controlled medically. Diabetes
and radiation primarily damage the retinal capillaries and
thus a potentiating effect is not surprising. Diabetes
results in early loss of pericytes and thickening of the base-
ment membrane. Radiation however, damages the
endothelial cells. As endothelial cells and pericytes are the
primary cells making retinal capillaries damage to these
cells, through a combination of diabetes and radiation,
leaves little cellular support. This would result in the visi-
ble changes of capillary closure, vessel leakage, aneurysms
and haemorrhage.
Radiation is being used with increasing frequency for ocu-
lar and orbital disease, because of this more cases of radi-
ation retinopathy may become prevalent. Factors which
may potentiate radiation retinopathy should be well
known including, increased radiation dosage, increased
fraction size, concomitant systemic vascular disease and
use of chemotherapy (See Table 1).
Counselling should be offered in all cases at risk of visual
loss. In some cases it may not be possible to protect the
eyes during radiation, in these cases one should be aware
of the factors which may potentiate eye disease, the dose
and area of the retina irradiated should be minimized.
As no effective treatment currently exists to restore visual
function, monitoring of visual acuity in all cases and early
referral to the ophthalmologist as appropiate is war-
ranted.
Further studies should be performed in order to produce
treatment guidelines for radiation retinopathy. Clinical
trials also need to be performed to establish whether early
PRP is beneficial in reducing the onset of radiation retin-
opathy in eyes at risk and also to determine if early PRP is
useful in inducing regression of established radiation
retinopathy and improve visual outcomes.
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